# US 2019/0240340 A1 · Functionalized nucleic acid nanostructures for rna delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0240340 A1
- Document ID: US20190240340A1
- Status: Published application
- Kind: A1
- Application number: 16/318,462
- Filed: 2017-07-20
- Published: 2019-08-08
- Earliest claimed: 2016-07-20
- Assignees: Guild BioSciences
- Applicants: Guild BioSciences
- Inventors: Ian Fleming; Xi Chun Zhou
- Web page: https://patentgrep.com/patent/US20190240340A1

## CPC

- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/351: Conjugate
- C12N 2310/3513: Protein; Peptide
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The present disclosure provides cell-penetrating nucleic acid nanostructures well suited as transfection reagents for the delivery of bioactive agents to cells both in vivo and in vitro for research, diagnostic, and/or therapeutic purposes.

## Claims

### Claim 1

A nucleic acid nanostructure, comprising:
a DNA or RNA scaffold;
at least one single stranded nucleic acid staple strand complementary to the scaffold;
at least one cell penetrating peptide attached to the at least one staple strand; and
at least one therapeutic substance attached to the at least one staple strand;
wherein the at least one cell penetrating peptide is positively charged,
wherein the at least one therapeutic agent is selected from the group: siRNA, miRNA, shRNA, asRNA, mRNA, crRNA, tracrRNA, and a RNA vaccine.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The nanostructure of claim 1, wherein the scaffold is assembled into a 24 helix bundle.

### Claim 4 (depends on 1)

The nanostructure of claim 1, wherein the at least one cell penetrating peptide and the at least one therapeutic substance are attached to the surface of the nanostructure.

### Claim 5 (depends on 1)

The nanostructure of claim 1, wherein the at least one therapeutic substance is capable of gene silencing or gene editing.

### Claim 6 (depends on 1)

The nanostructure of claim 1, wherein the nanostructure is capable of penetrating a cell using non-endocytic penetration.

### Claim 7 (depends on 1)

The nanostructure of claim 1, wherein the nanostructure includes non-conjugated overhangs and cell penetrating peptide-conjugated overhangs.

### Claim 8 (depends on 7)

The nanostructure of claim 7, wherein the nanostructure includes at least ten nonconjugated single-stranded overhangs for every cell penetrating peptide-conjugated single-stranded overhang.

### Claim 9 (depends on 7)

The nanostructure of claim 7, wherein the at least one therapeutic compound is attached to one or more of the non-conjugated overhangs.

### Claim 10

A method of treating a subject, the method comprising:
providing a nucleic acid nanostructure having:
a DNA or RNA scaffold;
at least one single-stranded nucleic acid staple strand complementary to the scaffold;
at least one positively charged cell penetrating peptide attached to the at least one staple strand; and
at least one therapeutic substance attached to the at least one staple strand;
wherein the at least one therapeutic agent is selected from the group: siRNA, miRNA, shRNA, asRNA, mRNA, crRNA, tracrRNA, or a RNA vaccine;
administering a therapeutically effective amount of the nucleic acid nanostructure to a subject.

### Claim 11 (depends on 10)

The method of claim 10, wherein the method is a method for treating cancer.

### Claim 12

(canceled)

### Claim 13 (depends on 10)

The method of claim 10, wherein the at least one cell penetrating peptide and the at least one therapeutic substance are attached to the surface of the nanostructure.

### Claim 14 (depends on 10)

The method of claim 10, wherein the at least one therapeutic substance is capable of gene silencing or gene editing.

### Claim 15 (depends on 10)

The method of claim 10, wherein the nanostructure is capable of penetrating a cell using non-endocytic penetration.

### Claim 16 (depends on 10)

The method of claim 10, wherein the nanostructure includes non-conjugated overhangs and cell penetrating peptide-conjugated overhangs.

### Claim 17 (depends on 10)

The method of claim 10, wherein the method is a method for treating a genetically-related condition.
